SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file ...

With a purchase price of $256 million, some investors might think the valuation is a bit rich for a business in such a dire position as 23andMe, but it won't put a huge dent into Regeneron's ...

Recently, Regeneron (REGN +0.45%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. You might remember that the genetic testing company ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer for ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Co-founder Anne Wojcicki is set to regain control of DNA-testing company 23andMe. 23andMe said late Friday that ...

Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Stream Los Angeles News for free, 24/7, wherever you ...

The bidding competition over 23andMe may not be over. The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, saying she ...

The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push bids higher than a current $256 million offer from Regeneron Pharmaceuticals ...

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out. Regeneron's purchase is still ...

Have you ever wondered if an established drugmaker could do better at genetics-guided research than a consumer-focused diagnostics business? Well, we could find out. Where to invest $1,000 right now?